Perimenopause vs. Menopause: A Plain-Language Guide to Hormone Therapy Options

Hot flashes at 47, with periods still arriving some months. Or a full year since your last period, and sleep that has not been the same. These are two different stages, and the difference matters for hormone therapy.

Perimenopause or menopause: how to tell

Menopause is a date you only know in hindsight: 12 months in a row without a period. The average age is 51. Perimenopause is the transition before it. Cycle length and bleeding patterns change, hormone levels swing, and symptoms can begin. The transition may last several years, and hot flashes may continue for seven years or more.

After 45, you do not need a hormone test to tell which stage you are in. A 2025 European Society of Endocrinology guideline, endorsed by the Endocrine Society, says testing is not necessary at that age for diagnosis or management. Hormone levels fluctuate for years, so a normal result does not rule perimenopause out. Testing can be considered between 40 and 45 and is recommended when symptoms begin before 40.

We still order labs before prescribing, to look for other causes of your symptoms and to set a baseline.

The three hormones, and what each one does

Estrogen

Estrogen can relieve hot flashes and night sweats, and the 2025 guideline notes that hormone therapy prevents bone loss and reduces fracture risk. For vaginal dryness or painful sex, the Endocrine Society recommends low-dose vaginal estrogen when moisturizers and lubricants are not enough. That advice is for women without a hormone-dependent cancer. Vaginal estrogen works locally, and the Society suggests no progestogen is needed with a low dose.

Progesterone

If you have a uterus, estrogen alone raises the risk of endometrial cancer. Adding a progestogen, such as progesterone, lowers that risk, so guidelines recommend the combination. After a hysterectomy, estrogen alone is the standard.

Testosterone

No testosterone product is FDA-approved for women, so any use is off-label or compounded. A 2019 global consensus statement found one evidence-based use: distressing low sexual desire after menopause, diagnosed after a full assessment. The average benefit was about one additional satisfying sexual event per month. It found no demonstrated effect on mood, well-being, or bone density, and too little data to make any recommendation before menopause. It advised against forms that push levels above the normal female range, naming pellets and injections.

Pills, patches, creams, troches, and pellets

FDA-approved hormone therapy comes in oral forms, forms absorbed through the skin such as patches and gels, and local vaginal products. The FDA notes that it has approved drugs containing hormones identical to the ones women make naturally. In that sense, they are already "bioidentical."

Route matters. In the 2025 guideline, estrogen through the skin is preferred for women with well-controlled diabetes or well-controlled high blood pressure. It is also suggested for women with a history of migraine with aura. The Endocrine Society recommends a non-oral route for women at increased risk of blood clots.

Troches (lozenges that dissolve under the tongue), pellets, and many creams are different. They are made to order by compounding pharmacies, and compounded medications are not FDA-approved. The FDA says it has no evidence that compounded "bioidentical hormones" are safe and effective, or safer or more effective than approved hormone therapy. The Endocrine Society recommends FDA-approved preparations and advises against custom-compounded hormones.

In the 2025 guideline's review, hot flashes did not respond to low-dose progesterone cream. The authors note that the cream is not well absorbed compared with oral micronized progesterone. A hormone is compounded when a dose or delivery method, such as a troche or pellet, is not available as an approved product. If we recommend a compounded form, we tell you so. Pellets for women typically last three to five months and cannot be removed or adjusted once placed.

Timing: who is a candidate, and when

For bothersome symptoms, the 2025 guideline recommends starting hormone therapy within 10 years of menopause or before age 60. Updated FDA labels tell prescribers to consider starting in that same window. Your stage changes the details:

• In perimenopause: the guideline includes appropriate candidates who still have periods. Hormone therapy may cause breakthrough bleeding while you are still cycling. The Menopause Society notes that combined hormonal birth control (a pill, patch, or ring) is frequently used instead, which also covers contraception.
• After menopause: the clock starts at your final period. Starting later shifts the balance of benefit and risk, so that decision is individual.
• Past 60 and already on therapy: the guideline suggests deciding case by case whether to continue, because benefits and risks change with age.
• Menopause before 40: the guideline recommends hormone therapy until the usual age of menopause, with or without symptoms.

Hormone therapy is generally not used in women with:

• Unexplained vaginal bleeding
• Breast cancer, now or in the past, or another estrogen-dependent cancer
• A past blood clot, stroke, or heart attack
• Liver disease
• A known blood-clotting disorder
• A known or suspected pregnancy

What current guidance says about risk

From 2003, FDA label changes based on the Women's Health Initiative trials came to include boxed warnings. Trial participants averaged 63 years old. In November 2025, the FDA asked manufacturers to remove the boxed warnings about cardiovascular disease, breast cancer, and probable dementia. Updated labels began appearing in February 2026.

The risks did not disappear. Warnings about cardiovascular disease and breast cancer remain in the labels. Systemic (whole-body) estrogen-alone products keep a boxed warning about endometrial cancer in women with a uterus.

The labels now include trial data for women aged 50 to 59. Per 10,000 women per year, compared with placebo:

• Combined estrogen and progestin pills: about 6 more breast cancers, 5 more strokes, 5 more coronary heart disease events, 10 more deep-vein clots, and 6 more clots in the lungs.
• Estrogen alone, studied in women without a uterus: about 5 more deep-vein clots and 4 more clots in the lungs, with no increase in stroke or breast cancer.

In this age group, most of these differences were not statistically significant; the exception was deep-vein clots with combined therapy. Across all ages in the combined-therapy trial, 50 to 79, each increase was larger. The labels cite a large analysis of prospective studies of longer use, 5 to 14 years. Compared with never-users, breast cancer risk was about double with combined therapy and about one-third higher with estrogen alone. Each trial tested one oral formulation. The labels say the risks cannot be ruled out for other doses, routes, or products.

Hormone therapy treats symptoms. The 2025 guideline recommends against using it primarily to prevent cardiovascular disease, or to prevent stroke or dementia. It also recommends telling every woman who starts about the increased risk of breast cancer.

Guidelines call for a review about three months after starting and at least yearly after that. Report any unexpected bleeding; persistent unscheduled bleeding needs evaluation.

The bottom line

Perimenopause and menopause call for the same careful steps: your history, your symptoms, the right labs, and a plan built for you. The details differ: contraception, timing, and which hormones you need. At Reset You MD, dosing is individualized and labs are rechecked along the way. If you are weighing hormone therapy, book a complimentary consultation. We will review your history and tell you plainly which options fit and which do not.

Website content is for general education and does not replace individualized medical advice, diagnosis, or treatment. Individual results vary. This article is general education from a Florida physician and does not create a doctor–patient relationship; talk with your own clinician about your situation.